BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

GlycoMimetics, Inc. (GLYC) Finally Prices Upraised IPO At $8 Per Share


1/9/2014 7:24:22 PM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

GlycoMimetics Announces Pricing of Initial Public Offering

GAITHERSBURG, Md.--(BUSINESS WIRE)--GlycoMimetics, Inc. today announced the pricing of its initial public offering of 7,000,000 shares of common stock at a price to the public of $8.00 per share. The shares are scheduled to begin trading on the NASDAQ Global Market under the ticker symbol "GLYC" on January 10, 2014. All of the common stock is being offered by GlycoMimetics. In addition, GlycoMimetics has granted the underwriters a 30-day option to purchase up to 1,050,000 additional shares of common stock from GlycoMimetics. The offering is expected to close on January 15, 2014, subject to customary closing conditions.

Jefferies LLC and Barclays Capital Inc. are acting as joint book-running managers for the offering. Stifel is acting as co-lead manager and Canaccord Genuity Inc. is acting as co-manager.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on January 9, 2014.

The offering is being made only by means of a prospectus. A copy of the final prospectus relating to these securities will be filed with the SEC and may be obtained, when available, from Jefferies LLC, Equity Syndicate Prospectus Department, 520 Madison Avenue, 12th Floor, New York, NY 10022, by email at Prospectus_Department@Jefferies.com or by phone at 877-547-6340 or Barclays Capital Inc., c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, by email at Barclaysprospectus@broadridge.com or by phone at 888-603-5847.

This press release shall not constitute an offer to sell or a solicitation of an offer to buy, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About GlycoMimetics, Inc.

GlycoMimetics is a clinical stage biotechnology company focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using its expertise in carbohydrate chemistry and knowledge of carbohydrate biology, GlycoMimetics is developing a pipeline of glycomimetic drug candidates that inhibit disease-related functions of carbohydrates, such as the roles they play in inflammation, cancer and infection.

Contacts

GlycoMimetics, Inc.
Brian Hahn, 240-243-1207
bhahn@glycomimetics.com

Help employers find you! Check out all the jobs and post your resume.


Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES